Tumors recycle glucocorticoids to drive Treg-mediated immunosuppression

Julian Swatler, … , Ana C. Anderson, Enrico Lugli

*J Clin Invest*. 2023;133(18):e173141. [https://doi.org/10.1172/JCI173141](https://doi.org/10.1172/JCI173141).

**Commentary**

Suppression of antitumor immunity is a prominent feature of the tumor microenvironment. In this issue of the *JCI*, Taves, Otsuka, and authors show that glucocorticoids (GCs), which are potent immunosuppressive hormones mainly produced by the adrenals, can be reconverted from their inactive form to active metabolites via the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme expressed by murine tumor cell lines. In the tumor microenvironment, GCs acted on CD4+ regulatory T cells to enhance their immunosuppressive function and promote tumor growth. The findings suggest that targeting GC recycling as a strategy for modulating tumor immunosuppression has the potential to improve therapeutic efficacy of immune checkpoint blockade.

Find the latest version:

[https://jci.me/173141/pdf](https://jci.me/173141/pdf)
Glucocorticoids mediate immunosuppression

Immunosuppression is a prominent feature of cancer development, restraining antitumor effector T cell responses and limiting efficacy of therapeutic interventions. Immunosuppression can be mediated by multiple mechanisms, including immunosuppressive cells, such as CD4 + Tregs and suppressive myeloid cells, immunoregulatory cytokines, such as TGF-β, or enzymes, such as CD39 or arginase-1, that produce inhibitory metabolites. Recently, steroid hormones, namely androgens and glucocorticoids (GCs), have also been implicated in tumor immunosuppression (1), leading to CD8 + T cell dysfunction, prevention of effector differentiation (2), and diminished glycolytic metabolism (3), overall resulting in reduced antitumor activity. Moreover, GC receptor (GR) expression and signaling have been shown to upregulate PD-L1 and downregulate MHC class I expression by pancreatic ductal adenocarcinoma (PDAC) cells, enabling evasion of antitumor immunity (4). However, the potential origin of immunoregulatory GCs in the tumor milieu is not entirely clear.

The primary source of GCs in the body is the adrenals, where several enzymes sequentially break down cholesterol to produce active GCs — cortisol (in humans) and corticosterone (in mice). Recent reports have shown that this pathway can also be active in intratumoral leukocytes, such as monocytes/macrophages and T cells, leading to evasion of antitumor immunity (2, 5). Active GCs can be further inactivated into cortisone (or dehydrocorticosterone [DHC] in mice), but recycled back to active GCs by the enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). Several organs express the 11β-HSD1 enzyme, potentially enabling alternative GC production (6, 7).

Related Article: https://doi.org/10.1172/JCI164599

Conflict of interest: EL receives research grants from Bristol Myers Squibb and serves as a consultant for BD Biosciences. ACA is a member of the scientific advisory board for Tizona Therapeutics, Trishula Therapeutics, Compass Therapeutics, Zymotur Biologics, ImmuneOncia, and Excepgen, which have interests in cancer immunotherapy. ACA is also a paid consultant for Iteos Therapeutics and Larkspur Biosciences.

Copyright: © 2023, Swatler et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.

Reference information: J Clin Invest. 2023;133(18):e173141. https://doi.org/10.1172/JCI173141.
promote tumor growth (6). Analyses of the immune infiltrate in 11β-HSD1-deficient B16 tumors revealed expansion of effector memory CD8+ T cells, increased production of TNF and IFN-γ by CD8+ T cells, and finally, increased mTORC2/riotor levels in Tregs whose expression has been associated with attenuated suppressive function.

It has been widely recognized that Tregs are highly abundant in tumors and are markedly affected by GCs. In models of autoimmune (experimental autoimmune encephalomyelitis [EAE]) and allergic (airway hyperreactivity) inflammation, Tregs have been shown to be necessary for the antinflammatory function of GCs, since dexamethasone, a synthetic GC, is unable to control inflammation in mice with GR-deficient Tregs (9). Along the same line, GCs drive Treg differentiation in the thymus and periphery, promote secretion of the immunosuppressive cytokine IL-10, and enhance Treg-mediated control of experimental colitis in mice (8). However, little is known about GC modulation of Tregs in a tumor setting.

To address this aspect, Taves, Otsuka, and colleagues used mice deficient in the GR specifically in the Treg lineage (Nr3c1 Foxp3-cre mice) and found that B16 and Panc02 tumor growth was reduced. Moreover, when 11β-HSD1-deficient B16 was used, the effect of Treg-specific GR deletion was diminished, supporting the premise that GC recycling by tumor cells acts via Tregs to promote tumor growth. Curiously, the quantity of Tregs was unaffected in Nr3c1 Foxp3-cre mice, implying the differences in tumor growth could be attributed to Treg functionality as opposed to homeostasis. Bulk RNA-Seq and gene set enrichment analysis revealed that tumor Tregs in Nr3c1 Foxp3-cre mice adopted features of activated conventional T cells, whereas tumor Tregs from Nr3c1 WT control mice resembled more activated Tregs. Although the suppressive capacity of Tregs was not assessed directly, these observations raise the possibility that in the absence of GC signaling, Tregs may become fragile and less suppressive (6, 10).

GC biogenesis pathways and their immunoregulatory functions are conserved between mice and humans. With this in mind, Taves, Otsuka, and colleagues mined The Cancer Genome Atlas (TCGA) and Oncomine databases of human tissues using bioinformatic approaches and found that, similarly to what occurs in mice, the HSD11B1 gene is expressed across almost all tissues of the body. Crucially, HSD11B1 expression was higher in both solid tumors and lymphomas compared with matched healthy adjacent tissue. Further, HSD11B1 expression positively correlated with expression of effector Treg genes (CCR8, CTLA4, ICOS, IL1R2) and of genes encoding checkpoint receptors (PDCD1, LAG3, HAVCR2, TIGIT) (6). The latter is consistent with the direct transactivation of these genes by the GR (2). Accordingly, calculation of estimated frequencies of immune cell populations in TCGA data sets revealed a positive correlation of HSD11B1 gene expression with Treg infiltration into tumors. However, in Taves, Otsuka, et al., Treg-specific deletion of GR in mice did not affect those Treg genes correlating with HSD11B1 in humans which were generally expressed by highly immunosuppressive Tregs (11); overall Treg numbers were also unaffected (6). Hence, it remains possible that the correlation found between levels of HSD11B1 and Treg infiltration in human cancers is an epiphhenomenon reflecting the level of inflammation in the tissue rather than a direct causal relationship of GC signaling with Treg suppression and infiltration. Clarifying these aspects would have important implications for translation in humans.

**Implications and conclusions**

GCs are potently immunosuppressive. Dampening their effect could have major consequences in reinvigorating the antitumor immune response; however, GCs are important for normal body homeostasis, making global targeting problematic (12). In this regard, the role of GC recycling by 11β-HSD1 in Treg-mediated immunosuppression indicates a possible avenue for therapeutic targeting. To complement the experiments in Taves, Otsuka, et al. in which 11β-HSD1 was deleted using genetic tools, the authors utilized two pharmacological inhibitors of 11β-HSD1 and showed attenuation of B16 melanoma tumor growth similar to that obtained by genetic deletion. Furthermore, pharmacological inhibition was tested in tumors developed from cell lines obtained from a genetically engineered melanoma model that reflects human triple wild-type (BRAF/RAF/NF1-WT) melanoma and its response to immunotherapy. Also, in this model, inhibition of 11β-HSD1 delayed tumor growth and, moreover, sensitized tumor cells to anti–PD-1 treatment, suggesting that GC inhibition may increase the effectiveness of immune checkpoint blockade in the clinic. These results align with the demonstration that loss of GC signaling in CD8+ T cells improves responses to anti–PD1 in mice bearing MC38-OvaΔm tumors (2). Thus, targeting of GC recycling rather than its biogenesis per se may provide an attractive avenue for improving therapeutic efficacy of immune checkpoint blockade, although systemic consequences and overall toxicity of this approach were not investigated in detail (6).

In summary, Taves, Otsuka, et al. identified a mechanism of immunosuppression in the tumor microenvironment, namely, localized GC production by tumor cells via recycling of inactive metabolites that in turn act on tumor-infiltrating Tregs (6). These findings add to previously published results on the role of GC signaling in promoting CD8+ T cell dysfunction (2). They also pave the way for further studies aiming to interfere with GC metabolism in combination with immune checkpoint blockade to promote potent and durable T cell responses.

**Acknowledgments**

This work has been supported by Italian Ministry of Health grant Giovani Ricercatori GR-2018-12367258 (to EL) and NIH grant CA229400 (to ACA). JS is supported by European Molecular Biology Organization (EMBO) postdoctoral fellowship ALTF 663-2022.

Address correspondence to: Enrico Lugli, Laboratory of Translational Immunology, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano (MI), Italy. Phone: 39.02.8224.5143; Email: enrico.lugli@humanitasresearch.it.

3. Konishi A, et al. Glucocorticoid imprints a low glucose metabolism onto CD8+ T cells and induces the